Trial Profile

A supplemental clinical trial of AT-GAA in ERT-treatment naïve Pompe patients

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 03 Jul 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cipaglucosidase alfa (Primary)
Indications Glycogen storage disease type II
Focus Adverse reactions

Most Recent Events

03 Jul 2018 New trial record
26 Jun 2018 According to an Amicus Therapeutics media release, the design of this study has been discussed with the Scientific Advice Working Party (SAWP) within the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
26 Jun 2018 According to an Amicus Therapeutics media release, this study is expected to start in 2019.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com